GlassScriptPhysician profile
Amanda W Sun
NPI 1194785964
$4,270.52
in general payments reported to CMS, 2019-2025
11 companies · $543 in 2025
The $543 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $99.95 · 2022: $167 · 2023: $3,048 · 2024: $243 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,275 · Food and Beverage: $999 · Honoraria: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,275.00 |
| Food and Beverage | $998.50 |
| Honoraria | $560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $2,275.00 | 2023 | Brukinsa |
| Daiichi Sankyo INC. | $560.00 | 2023 | |
| Lilly USA, LLC | $388.78 | 2019-2025 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $298.89 | 2022-2025 | Enhertu |
| Stemline Therapeutics INC. | $246.52 | 2023-2025 | Orserdu, Elzonris |
| Genentech, INC. | $132.13 | 2025 | Itovebi |
| Eisai INC. | $124.64 | 2024 | |
| Nevro Corp. | $102.96 | 2019 | |
| Seagen INC. | $99.95 | 2020 | |
| Abbvie INC. | $21.72 | 2025 | |
| Caris Mpi, INC. | $19.93 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.